As the file enclosed.

Pat Growth 25pctEbitda Margin ExpansionRevenue Growth 20pctResults View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.1%Reaction day

₹1160.00

prior close

₹1219.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.0%+5.1% vs market

Pharmaceuticals peers, median of 164sector+0.1%+5.0% vs sector

On the reaction day the stock moved 5.1 pts more than Nifty Microcap 250 and 5.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.1-0.0+5.1+0.1+5.0

Next day

+10.3-0.7+11.0-0.6+10.9

+15.9-1.8+17.6-1.3+17.2

+21.7-0.7+22.4-1.4+23.1

+27.7-0.5+28.2-1.6+29.3

+34.1+0.4+33.7-0.6+34.7

+41.9-1.6+43.5-2.3+44.2

15d

+48.5+4.6+43.9+0.0+48.5

+66.3+4.6+61.7+3.0+63.3

+35.6+6.1+29.4+4.3+31.3

+37.9+10.8+27.1+8.6+29.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venus Remedies Ltd reported strong FY2026 audited results with standalone revenue from operations of Rs. 768.73 crore, up 19.3% from Rs. 644.47 crore in FY25. Net profit jumped 89% to Rs. 99.31 crore from Rs. 52.55 crore, while consolidated net profit grew 127% to Rs. 102.78 crore. EBITDA rose 71% to Rs. 155.37 crore on standalone basis. The Board recommended a final dividend of Rs. 10 per share (100%) subject to shareholder approval at the 37th AGM on August 20, 2026 (record date: August 7, 2026). Statutory auditors issued an unmodified (clean) opinion on both standalone and consolidated results. The company has a German subsidiary (Venus Pharma GmbH) and a step-down Hungarian subsidiary.

Likely market impact

Venus Remedies delivered exceptional double-digit growth in both revenue and profitability, with EBITDA margin expansion indicating improved operational efficiency. The clean audit opinion and positive cash flows from operations (Rs. 151 crore standalone) signal financial health, supporting bullish sentiment for the stock ahead of the dividend payout.